

IN THE CLAIMS

Please amend Claims 28 and 29 as follows:

28. (Amended) A method for selectively destroying a cell expressing a PROST 03 polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein the method comprises reacting an immunoconjugate comprising an isolated monoclonal antibody, or antibody fragment, which specifically binds to one or more epitopes present in the PROST 03 polypeptide conjugated to a therapeutic agent with the cell, so that the therapeutic agent of the immunoconjugate can destroy the cell.

*A<sub>2</sub>*

*but not for metastatic prostate cancer + diseases ?*  
*metastatic prostate cancer + disease ?*  
*metastatic cells*

29. (Amended) A method of treating prostate cancer in a human patient, wherein the method comprises administering to the patient a therapeutically effective amount of an immunoconjugate comprising an isolated monoclonal antibody, or antibody fragment, which specifically binds to one or more epitopes present in a PROST 03 polypeptide having the amino acid sequence of SEQ ID NO: 2, conjugated to a therapeutic agent.

*check enable*  
*one Ab binds to + epitopes ?*  
*Ab to*  
*cell*  
*epitope*

REMARKS

Reconsideration of this application is respectfully requested. Claims 28 and 29 are pending in this application, having been elected by the Applicant in response to a Restriction Requirement (paper 6, mailed May 7, 2002). Claims 1-27 and 30-38 have been withdrawn from consideration, being drawn to non-elected inventions. Applicants reserve the right, under 35 U.S.C. 120, to pursue the non-elected subject matter in separate divisional applications.

Claims 28 and 29 have been amended to remove dependency on non-elected Claim 24, and to better describe the claimed invention.